Table 2.
Group DO (n=34) | Group DA (n=33) | p | |
---|---|---|---|
Nausea (VRS≥4) | |||
0 min | 2 (6%) | 2 (6%) | 1 |
0–30 min | 4 (12%) | 6 (18%) | 0.46 |
30–60 min | 1 (3%) | 2 (6%) | 1 |
60–90 min | 2 (6%) | 1 (3%) | 1 |
90–120 min | 1 (3%) | 0 | 1 |
2–24 h | 4 (12%) | 3 (9%) | 1 |
Retching | |||
0–2 h | 3 (9%) | 0 | 0.23 |
2–24 h | 1 (3%) | 0 | 0.16 |
Vomiting | |||
0–2 h | 0 | 1 (3%) | 0.49 |
2–24 h | 1 (3%) | 1 (3%) | 1 |
Rescue antiemetic | |||
0–24 h | 9 (26%) | 10 (30%) | 0.87 |
Complete response | |||
0–24 h | 23 (67%) | 23 (69%) | 0.93 |
Tramadol consumption | 252±94 | 255±100 | 0.90 |
Group DO: dexamethasone-ondansetron group; Group DA: dexamethasone-aprepitant group